Why Most Patent Claim Drafting Strategies Leave Commercialization Value on the Table

Patent attorneys and technology transfer professionals share a working relationship that is cordial, productive, and persistently misaligned. The attorney's job is to get a patent granted. The TTO's job is to get that patent licensed. Those two goals sound identical. They produce very different documents.

Photo by Pavel Danilyuk on Pexels.

Here's where the gap opens: most patent claims are drafted with the patent examiner as the primary audience. The claims get narrowed during prosecution to avoid prior art, to overcome rejections, to survive the process. That's rational behavior. It's also how you end up with an issued patent that describes your technology precisely, defends a very specific embodiment, and leaves every adjacent commercialization path completely unprotected.

Licensees don't care about the embodiment you built. They care about the market they want to enter. Those two things overlap less than most inventors assume.

The Claim Scope Problem Nobody Talks About in Prosecution

When a patent application comes through the door of a prosecution firm, the attorney typically gets the invention disclosure, maybe a technical paper, and a conversation with the inventor. What they rarely get: a market map, a product development roadmap, or any analysis of how a licensee might actually use this technology three years from now.

So the claims get written around what the inventor built and what prior art allows. That's understandable. But consider what a licensee actually needs from a patent:

• Exclusivity that covers the product they want to sell, not just the lab prototype
• Claim scope broad enough to block design-arounds that competitors will inevitably attempt
• Coverage across formulations, configurations, or use cases they plan to develop

Narrow prosecution answers none of those questions. A claim that protects "a catalyst comprising X with particle size between 50 and 75 nanometers" is defensible to an examiner. To a licensee whose product uses 80-nanometer particles, it's worthless.

What Good Claim Strategy Actually Requires

The fix isn't complicated. It is, however, organizational. Patent prosecution strategy needs commercial input at the drafting stage, before the first office action, before arguments get made that foreclose future claim scope.

Practically, that means a few things:

TTO staff need to engage before prosecution begins. Not to review the final application, but to ask the question: what does a licensee in this space actually need to be protected? That requires knowing the competitive landscape well enough to anticipate design-arounds.

Claim families should cover multiple commercial scenarios. The independent claim protects the core invention. Dependent claims should walk through the product variations, delivery methods, and applications a licensee is likely to pursue. This isn't over-claiming; it's covering the commercialization space systematically.

Prosecution history estoppel deserves more attention than it gets. Arguments made to distinguish prior art during prosecution limit how broadly claims can later be interpreted in litigation or licensing disputes. Inventors and TTOs often don't realize that the words their attorney wrote to overcome a rejection become a ceiling on future interpretations. That ceiling can be lower than the deal you're trying to close.

graph TD
    A[Invention Disclosure] --> B{Commercial Input?}
    B -->|No| C[Claims Drafted Around Embodiment]
    B -->|Yes| D[Claims Drafted Around Market Space]
    C --> E[Narrow Prosecution]
    D --> F[Broad Claim Family]
    E --> G(Weak Licensing Position)
    F --> H(Defensible License Grant)

The Timing Problem Is Structural

Most universities have a workflow problem here that predates any individual attorney or TTO staffer. Patent prosecution runs on legal timelines. Commercialization assessment runs on market timelines. The two calendars don't sync naturally, and nobody has historically owned the job of making them sync.

Result: the invention disclosure gets filed, the application gets drafted, prosecution proceeds, the patent issues, and then the TTO tries to license it. Licensing staff discover the claim scope doesn't cover the product anyone actually wants to sell. The patent has value; just not the right kind of value for the deal in front of them.

Some offices have started requiring a brief commercial assessment alongside every invention disclosure. A one-page document: who are the likely licensees, what product would they build, what would a competitor do to design around this? That document goes to the patent attorney before drafting. It costs almost nothing to produce. It changes the patent substantially.

The Relationship Worth Building

Patent attorneys who work with universities regularly are often excellent at prosecution. The ones who become genuinely valuable to a commercialization program are the ones who understand licensing deals well enough to anticipate what a licensee will need from the claims they're writing today.

That relationship takes time to build and requires the TTO to share commercial context proactively. Most TTOs don't do this consistently. When they start, the quality of their patent portfolio shifts in ways that show up in licensing conversations two and three years later.

Claims don't have to be written for licensees instead of examiners. They have to be written for both. The attorney who understands that difference is worth finding and keeping.